Point72 Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
Point72 Asset Management's RXRX Position: Q3 2026 in Review
Point72 Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q3 2026: 238,435 shares worth $985K. The stake represents ﹤0.01% of the portfolio and ranks #2796 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in RXRX as recently as Q4 2025.
Point72 Asset Management first reported a position in RXRX in Q3 2023 and has held it in 5 quarters since. The position peaked at $14.5M in Q4 2023. 353 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.
- Point72 Asset Management held 238,435 shares of Recursion Pharmaceuticals worth $985K as of Q3 2026.
- Recursion Pharmaceuticals was a new Point72 Asset Management position in Q3 2026.
- Recursion Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q3 2026, its #2796 holding.
- Point72 Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
- Point72 Asset Management's Recursion Pharmaceuticals position peaked at $14.5M in Q4 2023.
- 353 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.
Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.